<div id="readability-page-1"><p>TScan Therapeutics (NASDAQ:TCRX - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.07, FiscalAI reports. The business had revenue of $2.51 million during the quarter, compared to the consensus estimate of $1.98 million. TScan Therapeutics had a negative return on equity of 63.33% and a negative net margin of 1,964.88%.</p><div><p><span></span><span>Get <strong>TScan Therapeutics</strong> alerts:</span></p></div><h2>TScan Therapeutics Stock Performance</h2><p>TCRX stock traded down $0.04 during mid-day trading on Wednesday, hitting $1.18. The company had a trading volume of 414,920 shares, compared to its average volume of 507,574. The firm has a market cap of $66.97 million, a PE ratio of -1.08 and a beta of 1.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 7.06 and a current ratio of 7.06. TScan Therapeutics has a 12 month low of $1.02 and a 12 month high of $5.56. The stock's fifty day moving average price is $1.88 and its two-hundred day moving average price is $1.71. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of research analysts have recently weighed in on the company. Wedbush  restated an &#34;outperform&#34; rating and issued a $7.00 target price on shares of TScan Therapeutics in a report on Tuesday, August 12th. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of TScan Therapeutics in a report on Wednesday, October 8th. BTIG Research lowered shares of TScan Therapeutics from a &#34;buy&#34; rating to a &#34;neutral&#34; rating in a research note on Tuesday, November 4th. Finally, Needham &amp; Company LLC dropped their price target on shares of TScan Therapeutics from $9.00 to $6.00 and set a &#34;buy&#34; rating on the stock in a research report on Tuesday, November 4th. Five research analysts have rated the stock with a Buy rating, one  has given a Hold rating and one  has issued  a Sell rating to the company's stock. Based on data from MarketBeat.com, the company  has an average rating of &#34;Moderate Buy&#34; and an average target price of $7.20.</p><p><b>Check Out Our Latest Research Report on TCRX</b></p><h2>Hedge Funds Weigh In On TScan Therapeutics</h2><p>Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of  TScan Therapeutics by 7.8% during the 3rd quarter. Vanguard Group Inc. now owns 2,317,916 shares of the company's stock valued at $4,219,000 after buying an additional 168,540 shares during the last quarter.  Militia Capital Partners LP purchased a new stake in  TScan Therapeutics in the 2nd quarter worth about $137,000.  Bridgeway Capital Management LLC raised its stake in  TScan Therapeutics by 35.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 153,700 shares of the company's stock valued at $223,000 after acquiring an additional 40,400 shares during the period.  Bank of America Corp DE raised its position in shares of  TScan Therapeutics by 28.0% in the second quarter. Bank of America Corp DE now owns 217,967 shares of the company's stock valued at $316,000 after purchasing an additional 47,617 shares during the period.  Finally, Jane Street Group LLC bought a new position in shares of  TScan Therapeutics in the second quarter worth $309,000. Hedge funds and other institutional investors own  82.83% of the company's stock. </p><h2>About TScan Therapeutics</h2> (Get Free Report)<p>TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than TScan Therapeutics</li><li>Value Investing: Is it a Good Strategy in 2022? <span>Hint: Always<span></span></span></li><li>Papa John's $2.7 Billion Takeover Bid: A Price on Untapped Value</li><li>Airline Stocks - Top Airline Stocks to Buy Now</li><li>Is Qualcomm Up 40% or Down 20%? 2 Contrarian Takes</li><li>Stock Analyst Ratings and Canadian Analyst Ratings</li><li>Guardian Pharmacy Stock Pops on Q3 Strength and Upbeat Forecast</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VENSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VENSWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in TScan Therapeutics Right Now?</h2><p>Before you consider TScan Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TScan Therapeutics wasn't on the list.</p><p>While TScan Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TCRX

<p>TScan Therapeutics reported quarterly earnings, beating estimates by $0.07 EPS. The company posted a ($0.28) EPS, surpassing the consensus of ($0.35). Revenue was $2.51 million, above the expected $1.98 million. Despite negative return on equity and net margin, analysts have mixed ratings, with a moderate buy consensus and a $7.20 average target price. Institutional investors hold 82.83% of shares. TScan develops TCR-T therapies for cancer treatment.</p>

TScan Therapeutics (NASDAQ:TCRX) Issues Quarterly Earnings Results, Beats Estimates By $0.07 EPS